Where does Gelesis, LLC rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Gelesis, LLC ranks #18,656 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Gelesis, LLC hold?

Gelesis, LLC holds 15 US utility patents granted between 2016 and 2023, spanning 13 technology areas.

What is Gelesis, LLC's Innovation Score?

Gelesis, LLC has an Innovation Score of 32.7 out of 100 (42nd percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Gelesis, LLC focus on?

Gelesis, LLC's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 15 patents, ranking #1,291 of 6,058 assignees active in that subclass. Grants appear in 13 CPC subclasses total.

Is Gelesis, LLC's patent grant rate increasing or decreasing?

Gelesis, LLC's recent grant velocity is +50% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Gelesis, LLC's patents?

Gelesis, LLC's patents average 14.9 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Gelesis, LLC patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Gelesis, LLC

USPTO PatentsView assignee record - 15 granted patents across 13 technology areas, recorded in grant years 2016–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Gelesis ranks #18,656 of 49,997 tracked US assignees by granted-patent volume, with 15 patents across 13 technology areas.

#18,656
of 49,997 US assignees by volume: 42nd percentile
by Innovation Score (32.7/100): 14.9
avg claims per patent: +50%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R18656 · US Corporation #18,656 · 15 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 15 grants
MID-PACK #18,656/49,997
PHOTO-FINISH Gateway Plastics
CPC-FOCUS A61P · 13 areas
INNOV-THIN 32.7/100
CLAIMS-RICH 14.9 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +50% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Gateway Plastics, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Gelesis’s 32.7 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 9.6 pts (29%) Velocity 1.5 pts (5%) Breadth 12.7 pts (39%) Claim depth 8.9 pts (27%)

Qualcomm Incorporated · highest

85
Gelesis · this assignee

33
3D Lighting… · lowest

7

What this shows Gelesis's Innovation Score is 32.7/100 (42nd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Gelesis?

Each dot is one of Gelesis’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Gelesis’s own 14.9 claims/patent is ABOVE the 14.5 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Gelesis vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Gelesis's grants concentrate

Gelesis, LLC is a focused PatentsView assignee: 13 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2021 (4 grants) versus a trough of 1 in 2016. By volume, Gelesis sits between Guild Associates Inc. and Genova Inc.

Gelesis's three-year grant acceleration

Gelesis, LLC shows 2 grants in 2022–2024 against only 9 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Guild Associates

15
Guntert & Zimmerm…

15
GV Engineering

15
Gateway Plastics

15
Gen-y Creations

15
General Instrument

15
Genocea Bioscienc…

15
Genova

15
Gelesis ◀

15

What this shows Gelesis holds 15 patents at rank #18,673, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Gelesis

By rank, the assignees closest to #18,673 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Gelesis's primary technology class.

Gelesis's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

33 42nd percentile higher than 42% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

Gelesis, LLC patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	1	6.7%
2018	3	20.0%
2019	2	13.3%
2020	3	20.0%
2021	4	26.7%
2022	1	6.7%
2023	1	6.7%

Which technologies does Gelesis, LLC patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 15

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 14

C08B - POLYSACCHARIDES; Derivatives Thereof 8

A23L - Foods, Foodstuffs OR Non-alcoholic Beverages, NOT Otherwise Provided FOR; Preparation OR Treatment Thereof 5

C08J - WORKING-UP; General Processes OF COMPOUNDING; After-treatment NOT Covered BY Subclasses C08b, C08c, C08f, C08g or C08h 5

C08L - Compositions OF Macromolecular Compounds 4

Y10T - Technical Subjects Covered BY Former US Classification 3

A61L - Methods OR Apparatus FOR Sterilising Materials OR Objects IN GENERAL; Disinfection, Sterilisation OR Deodorisation OF AIR; Chemical Aspects OF Bandages, Dressings, Absorbent Pads OR Surgical ARTICLES; Materials FOR Bandages, Dressings, Absorbent Pads OR Surgical Articles 2

A23V - Indexing Scheme Relating TO Foods, Foodstuffs OR Non-alcoholic Beverages AND Lactic OR Propionic Acid Bacteria Used IN Foodstuffs OR Food Preparation 1

Y02A - Technologies FOR Adaptation TO Climate Change 1

C08G - Macromolecular Compounds Obtained Otherwise Than BY Reactions Only Involving Unsaturated Carbon-to-carbon Bonds 1

Y02E - Reduction OF Greenhouse GAS [GHG] Emissions, Related TO Energy Generation, Transmission OR Distribution 1

Y02W - Climate Change Mitigation Technologies Related TO Wastewater Treatment OR Waste Management 1

Top 13 of 13 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Gelesis, LLC's patent record in context - here's where to go next.

Gelesis, LLC's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #18,656 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Gelesis, LLC against Guild Associates Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 32.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.